NNIT (NNIT) investor relations material

Executive summary

• Q3 revenue was DKK 409.6m, down 5.1% reported and 5.9% in constant currency; adjusted EBIT was DKK 22.2m, with a 5.4% margin.

• Performance was in line with expectations; lower revenue and project postponements weighed on results, partly offset by cost reductions, improved utilization and stronger US signings.

• OneNNIT 2030 focuses on international life sciences and regulated Danish sectors, integrating AI into offerings, delivery and internal operations.

Financial highlights

• Q3 revenue was DKK 409.6m versus DKK 431.6m; constant-currency decline was 5.9%, or 4.2% excluding Singapore.

• EBIT excluding special items was DKK 22.2m versus DKK 35.6m; reported operating profit including special items was DKK 3.6m versus DKK 27.7m.

• Special items were DKK 18.5m versus DKK 7.9m, predominantly restructuring costs; total costs fell DKK 9m YoY in Q3 and DKK 52m for 9M.

• Free cash flow was DKK 27m versus DKK 36m; positive operating cash flow benefited from working capital, while investment outflows were higher.

• 9M revenue was DKK 1,273.7m versus DKK 1,357.9m, down 6.2% reported and 5.8% in constant currency.

Outlook and guidance

• FY 2026 constant-currency revenue growth guidance narrowed to -1% to -6% from previously single-digit negative; improved performance, backlog and pipeline informed the revision.

• FY 2026 EBIT margin excluding special items remains guided at 4%-7%; special items are expected below FY 2025's DKK 83m.

• Guidance assumes no further macroeconomic deterioration, reflects the Singapore divestment and excludes a potential SCALES divestment.

• FY 2027 financial outlook is scheduled for release with the 2026 annual report on February 4, 2027; the new operating model is planned to take effect January 1, 2027.